Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial

NCT02401971 is registered in ClinicalTrials.gov with Wang Jufeng as lead sponsor.

NCT NCT02401971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02401971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial
Lead sponsor
Wang Jufeng
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2014
Completion date
August 31, 2018
Enrollment
900 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer